Drugs can wear costumes, too. This year, the darling of the pharmaceutical sector, the glucagon-like peptide 1 (GLP-1) agonist drug class, dressed up as a boogeyman, and set its sights on the medtech sector.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?